TWI804743B - 治療特發性肺纖維化的方法 - Google Patents

治療特發性肺纖維化的方法 Download PDF

Info

Publication number
TWI804743B
TWI804743B TW109121568A TW109121568A TWI804743B TW I804743 B TWI804743 B TW I804743B TW 109121568 A TW109121568 A TW 109121568A TW 109121568 A TW109121568 A TW 109121568A TW I804743 B TWI804743 B TW I804743B
Authority
TW
Taiwan
Prior art keywords
days
compound
pharmaceutically acceptable
stereoisomer
acceptable salt
Prior art date
Application number
TW109121568A
Other languages
English (en)
Chinese (zh)
Other versions
TW202114679A (zh
Inventor
趙焰平
王紅軍
姜媛媛
仲偉婷
趙靜
李晶
劉偉娜
周麗瑩
劉亞男
Original Assignee
大陸商北京泰德製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商北京泰德製藥股份有限公司 filed Critical 大陸商北京泰德製藥股份有限公司
Publication of TW202114679A publication Critical patent/TW202114679A/zh
Application granted granted Critical
Publication of TWI804743B publication Critical patent/TWI804743B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW109121568A 2019-06-25 2020-06-24 治療特發性肺纖維化的方法 TWI804743B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019092675 2019-06-25
WOPCT/CN2019/092675 2019-06-25

Publications (2)

Publication Number Publication Date
TW202114679A TW202114679A (zh) 2021-04-16
TWI804743B true TWI804743B (zh) 2023-06-11

Family

ID=74061495

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109121568A TWI804743B (zh) 2019-06-25 2020-06-24 治療特發性肺纖維化的方法

Country Status (10)

Country Link
US (1) US12582653B2 (cg-RX-API-DMAC7.html)
EP (1) EP3992183B1 (cg-RX-API-DMAC7.html)
JP (1) JP7615061B2 (cg-RX-API-DMAC7.html)
CN (2) CN114026072A (cg-RX-API-DMAC7.html)
AU (1) AU2020305979B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021026214A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144113A1 (cg-RX-API-DMAC7.html)
IL (1) IL289192B1 (cg-RX-API-DMAC7.html)
TW (1) TWI804743B (cg-RX-API-DMAC7.html)
WO (1) WO2020259528A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118772118A (zh) * 2020-08-31 2024-10-15 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途
CA3209240A1 (en) * 2021-02-22 2022-08-25 Samuel D. Waksal Rock2 inhibitor for the treatment of viral infection
NO346587B1 (en) * 2021-06-02 2022-10-17 Axichem Ab Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
TW202327608A (zh) * 2021-09-17 2023-07-16 北京泰德製藥股份有限公司 治療病毒感染的方法
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
EP4434513A4 (en) * 2021-11-16 2025-11-19 Beijing Tide Pharmaceutical Co Ltd NANOCRYSTALLINE PREPARATION OF ROCK2 INHIBITOR AND ITS PREPARATION PROCESS
US20250074908A1 (en) * 2022-01-13 2025-03-06 Wuhan Createrna Science And Technology Co., Ltd. Salt of rock inhibitor, crystal form of salt, composition, and pharmaceutical use
TW202423441A (zh) * 2022-10-13 2024-06-16 大陸商北京泰德製藥股份有限公司 治療塵肺病的方法
WO2025017500A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations of rock2 inhibitors for cns disorders
AU2024292342A1 (en) 2023-07-17 2026-02-26 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
IL327381A (en) 2023-09-28 2026-05-01 Graviton Pharmaceuticals B V Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors
IL327385A (en) 2023-09-29 2026-05-01 Graviton Pharmaceuticals B V ROCK2 inhibitors in the treatment of obesity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019001572A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506571A (ja) 2015-02-27 2018-03-08 リセラ・コーポレイションLycera Corporation Rho関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物
TWI800498B (zh) * 2016-12-21 2023-05-01 義大利商吉斯藥品公司 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019001572A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho 相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Y Shimizu,et al. "ROCK activation in lung of idiopathic pulmonary fibrosis with oxidative stress", Int J Immunopathol Pharmacol. 2014 Jan-Mar; 27(1): 37-44. *

Also Published As

Publication number Publication date
WO2020259528A1 (zh) 2020-12-30
JP7615061B2 (ja) 2025-01-16
EP3992183B1 (en) 2026-07-15
JP2022539329A (ja) 2022-09-08
US20220233538A1 (en) 2022-07-28
EP3992183A4 (en) 2023-06-21
US12582653B2 (en) 2026-03-24
IL289192A (en) 2022-02-01
CN114026072A (zh) 2022-02-08
KR20220029681A (ko) 2022-03-08
IL289192B1 (en) 2026-05-01
EP3992183A1 (en) 2022-05-04
AU2020305979A1 (en) 2022-02-17
TW202114679A (zh) 2021-04-16
BR112021026214A2 (pt) 2022-02-15
CN119868365A (zh) 2025-04-25
AU2020305979B2 (en) 2026-04-23
CA3144113A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
JP7615061B2 (ja) 特発性肺線維症を治療する方法
KR102906316B1 (ko) 지방간 질환 및/또는 지방간염의 치료 방법
TW202304914A (zh) 經取代之四環羧酸、其類似物及使用其之方法
JP7663508B2 (ja) ジアミノピリミジン化合物を使用することによって、子宮内膜症性疼痛を治療する方法
JP7665529B2 (ja) ジアミノピリミジン化合物を使用することによって咳を治療する方法
WO2022017412A1 (zh) 治疗造血干细胞移植后的移植物抗宿主病的方法
HK40121343A (en) Method for treating idiopathic pulmonary fibrosis
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
EP4591863A1 (en) Method for treating pneumoconiosis
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis
JP2025529076A (ja) AhR媒介疾患の治療に使用するタピナロおよびそのアナログ製剤
HK40054971A (en) Method for treating fatty liver disease and/or steatohepatitis
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
HK40063168A (en) Method for treating cough by using diaminopyrimidine compound
EA041729B1 (ru) Соединение, композиция и применение для лечения гиперурикемии или подагры